Published in J Antimicrob Chemother on February 07, 2006
Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa. Clin Infect Dis (2009) 1.33
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother (2008) 1.30
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob Agents Chemother (2006) 1.25
Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob Agents Chemother (2009) 1.17
Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants. J Clin Microbiol (2009) 1.12
A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa. AIDS (2008) 1.11
Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro. Antimicrob Agents Chemother (2007) 1.05
G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not. Retrovirology (2011) 1.03
Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database. BMC Infect Dis (2008) 1.02
Quantitative detection of plasma human immunodeficiency virus type 2 subtype A RNA by the Nuclisens EasyQ Assay (version 1.1). J Clin Microbiol (2006) 0.97
Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings. AIDS Res Treat (2011) 0.96
Characteristics, immunological response & treatment outcomes of HIV-2 compared with HIV-1 & dual infections (HIV 1/2) in Mumbai. Indian J Med Res (2010) 0.95
Structural evidence for effectiveness of darunavir and two related antiviral inhibitors against HIV-2 protease. J Mol Biol (2008) 0.95
Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors. Protein Sci (2012) 0.91
Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir. Retrovirology (2010) 0.90
Development and evaluation of an oligonucleotide ligation assay for detection of drug resistance-associated mutations in the human immunodeficiency virus type 2 pol gene. J Clin Microbiol (2007) 0.89
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir. Antimicrob Agents Chemother (2007) 0.86
Revealing origin of decrease in potency of darunavir and amprenavir against HIV-2 relative to HIV-1 protease by molecular dynamics simulations. Sci Rep (2014) 0.86
Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy. Antimicrob Agents Chemother (2013) 0.84
How does curcumin work with poor bioavailability? Clues from experimental and theoretical studies. Sci Rep (2016) 0.83
HIV-2 Protease resistance defined in yeast cells. Retrovirology (2006) 0.82
HIV-2 diagnosis and quantification in high-risk patients. AIDS Res Ther (2008) 0.79
HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen. PLoS One (2014) 0.77
A modular system to evaluate the efficacy of protease inhibitors against HIV-2. PLoS One (2014) 0.76
Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors. J Virol (2015) 0.75
Inhibition Profiling of Retroviral Protease Inhibitors Using an HIV-2 Modular System. Viruses (2015) 0.75
Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis (2006) 5.24
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52
Care of patients with hepatitis C and HIV co-infection. AIDS (2004) 3.46
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med (2005) 3.17
Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS (2003) 3.14
Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis (2005) 2.73
Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis (2008) 2.72
Viral quasispecies evolution. Microbiol Mol Biol Rev (2012) 2.69
Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med (2013) 2.68
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis (2012) 2.43
High prevalence of HIV-1 subtype G and natural polymorphisms at the protease gene among HIV-infected immigrants in Madrid. AIDS (2002) 2.36
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med (2013) 2.25
Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis (2003) 2.11
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis (2008) 2.06
Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy. J Acquir Immune Defic Syndr (2006) 1.96
Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection. Expert Opin Pharmacother (2012) 1.95
High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. J Antimicrob Chemother (2010) 1.94
Lack of 'occult' hepatitis B virus infection in HIV-infected patients. AIDS (2002) 1.92
Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther (2005) 1.85
Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients. J Hepatol (2008) 1.84
Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis (2009) 1.81
Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. J Clin Microbiol (2008) 1.81
Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS (2009) 1.81
Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT. J Clin Microbiol (2005) 1.75
Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. AIDS (2002) 1.68
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS (2006) 1.68
Correlation between human immunodeficiency virus type 1 (HIV-1) RNA measurements obtained with dried blood spots and those obtained with plasma by use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV load tests. J Clin Microbiol (2009) 1.67
Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis (2005) 1.66
Mother-to-child transmission of human herpesvirus-8 in South Africa. J Infect Dis (2004) 1.64
Seroprevalence of HIV-1, HBV, HTLV-1 and Treponema pallidum among pregnant women in a rural hospital in Southern Ethiopia. J Clin Virol (2011) 1.63
Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus type I from a single donor. Transplantation (2003) 1.62
Optimal use of maraviroc in clinical practice. AIDS (2008) 1.60
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. Retrovirology (2009) 1.58
Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia. AIDS (2002) 1.55
Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring. AIDS Res Hum Retroviruses (2008) 1.53
Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1. Clin Infect Dis (2005) 1.52
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS (2005) 1.52
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS (2005) 1.52
Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS (2007) 1.52
Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr (2006) 1.49
HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother (2006) 1.46
Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. J Antimicrob Chemother (2006) 1.45
Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS (2004) 1.44
Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J Antimicrob Chemother (2009) 1.43
[Human immunodeficiency virus type 2 and human T-cell lymphotropic virus type 1 and type 2 infections in Spain: an update]. Enferm Infecc Microbiol Clin (2009) 1.43
Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J Clin Virol (2004) 1.42
Comparison of HIV-1 RNA measurements obtained by using plasma and dried blood spots in the automated abbott real-time viral load assay. J Clin Microbiol (2011) 1.42
Treatment of chronic hepatitis C virus infection: we must target the virus or liver fibrosis? AIDS (2003) 1.42
HCV-specific T-cell responses in HIV/hepatitis C virus-coinfected patients on highly active antiretroviral therapy are comparable to those observed in hepatitis C virus-monoinfected individuals. J Acquir Immune Defic Syndr (2011) 1.42
Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. J Antimicrob Chemother (2008) 1.42
Antiretroviral drugs and liver injury. AIDS (2008) 1.40
Normalization of liver enzymes in an HIV-hepatitis C virus-co-infected patient after potent antiretroviral therapy. AIDS (2002) 1.39
European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev (2011) 1.38
Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine (2006) 1.37
Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1. Clin Infect Dis (2005) 1.33
Performance of three commercial viral load assays, Versant human immunodeficiency virus type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, testing HIV-1 non-B subtypes and recombinant variants. J Clin Microbiol (2008) 1.32
Evaluation of performance across the dynamic range of the Abbott RealTime HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses. J Virol Methods (2006) 1.31
Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother (2007) 1.30
Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS (2002) 1.30
HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1. AIDS (2004) 1.29
Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother (2008) 1.29
Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS (2004) 1.28
Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection. AIDS (2004) 1.28
Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. J Antimicrob Chemother (2007) 1.28
Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2005) 1.28
Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother (2007) 1.27
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr (2006) 1.27
Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses (2007) 1.26
CD38 expression on CD8 T lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving antiretroviral therapy. AIDS Res Hum Retroviruses (2004) 1.26
Is natural conception a valid option for HIV-serodiscordant couples? Hum Reprod (2007) 1.25
Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS (2010) 1.24
Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother (2012) 1.24
HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS (2006) 1.23
Elite HIV controllers: myth or reality? AIDS Rev (2008) 1.21
Renal toxicity associated with tenofovir use. Expert Opin Drug Saf (2010) 1.21
Liver toxicity caused by nevirapine. AIDS (2002) 1.20
Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS (2004) 1.20
Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4(+) cells after antiretroviral therapy. J Infect Dis (2008) 1.19
The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology (2009) 1.18
Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis (2011) 1.18
Kaposi's sarcoma associated herpesvirus (KSHV) or human herpesvirus 8 (HHV8). Virus Res (2002) 1.17
Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS (2012) 1.16
Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS (2011) 1.16
Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor. AIDS (2002) 1.16
Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther (2008) 1.14
Predictors of virological response to atazanavir in protease inhibitor-experienced patients. HIV Clin Trials (2004) 1.12
Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther (2008) 1.12
Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes. AIDS Rev (2006) 1.11
Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. J Antimicrob Chemother (2009) 1.11
Lack of anti-HIV activity of entecavir in an HIV patient coinfected with hepatitis B and delta viruses. AIDS (2007) 1.10
Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia. J Antimicrob Chemother (2010) 1.10